Highlights of The Neurotechnology Industry 2007 Report


The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System is a 350-page market analysis and strategic investment guide of the global neurological disease and psychiatric illness markets.

The report focuses on the more than 500 public and private companies translating advances in neuroscience into tomorrow's treatments. It provides insight and analysis of issues such as corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry.

The report provides an in-depth look at fifteen brain and central nervous system disorders, including Alzheimer's disease, addiction, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, memory decline, obesity, pain, Parkinson's, psychiatric disorders, stroke and other brain-related illnesses.

Specific findings from the Neurotechnology Industry 2007 Report include:

  • Brain-related illnesses afflict more than two billion people worldwide

  • The worldwide economic burden of this problem has reached more than $2 trillion per year; more than $1 trillion in the U.S. alone

  • 2006 venture capital investment in neurotechnology rose 7.5% to $1.666 billion

  • Neurotech industry revenues rose 10% in 2006 to $120.5 billion; this includes neuropharmaceutical revenues of $101 billion, neurodevice revenues of $4.5 billion, neurodiagnostic revenues of $15 billion

  • The Neurotech Index of publicly-traded neurotechnology companies was up 53% from its December 31, 2003 conception to March 31, 2006, outpacing the NASDAQ Biotech Index which gained 7% during the same period

  • Up-to-date market data and detailed competitive intelligence for over 15 major neuropharma and neurodevice markets

  • Compounds and devices in clinical trials by company, mechanism of action, and stage of development

  • Profiles of 500 public & private neurotech - neuropharmaceutical, neurodevice, neurodiagnostic companies (see list)

  • Worldwide government research, private funding and public investment trends

  • Analysis of the 10 most active neurotech venture capital firms, including investments by market segment

  • Public neurotech investment trends, including a neurotech tracking index highlighting 30 public neurotech companies

  • Extensive discussion of the specific technological, demographic, regulatory, and IP trends driving neurotech

  • And much more...(see Table of Contents)
Purchase Now
$4500
Enter hard copy or pdf
and press purchase